Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
9.316
Zitationen
16
Autoren
2011
Jahr
Abstract
In patients with atrial fibrillation, rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism. There was no significant between-group difference in the risk of major bleeding, although intracranial and fatal bleeding occurred less frequently in the rivaroxaban group. (Funded by Johnson & Johnson and Bayer; ROCKET AF ClinicalTrials.gov number, NCT00403767.).
Ähnliche Arbeiten
Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis
2014 · 11.546 Zit.
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
2009 · 11.129 Zit.
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
2020 · 9.709 Zit.
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
2017 · 9.603 Zit.
Apixaban versus Warfarin in Patients with Atrial Fibrillation
2011 · 8.825 Zit.
Autoren
Institutionen
- Clinical Research Institute(US)
- Duke Medical Center(US)
- Duke University(US)
- Johnson & Johnson (United States)(US)
- Massachusetts General Hospital(US)
- Harvard University(US)
- Heidelberg University(DE)
- University Hospital Münster(DE)
- University of Münster(DE)
- Mount Sinai Medical Center(US)
- Royal Perth Hospital(AU)
- Bayer (United States)(US)
- University of Edinburgh(GB)
- Edinburgh Royal Infirmary(GB)